This randomized controlled trial aims to compare the efficacy of Methotrexate versus Apremilast in reducing pruritus and improving quality of life in patients with psoriasis. Eighty patients aged 20 to 60 years with psoriasis involving more than 8% body surface area and associated pruritus will be enrolled and randomly assigned into two groups. Group A will receive oral Apremilast titrated to 30 mg twice daily, while Group B will receive oral Methotrexate 10 mg once weekly for 8 weeks. The primary outcome will be change in Dermatology Life Quality Index (DLQI) score at 8 weeks. Secondary outcomes include change in numerical rating scale for pruritus and assessment of adverse effects. The study will be conducted at Pakistan Emirates Military Hospital Rawalpindi.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
80
Oral Apremilast titrated to 30 mg twice daily for 8 weeks.
Oral Methotrexate 10 mg once weekly for 8 weeks.
Pak Emirates Military Hospital
Rawalpindi, Punjab Province, Pakistan
Change in Dermatology Life Quality Index (DLQI) Score
Difference between baseline DLQI score and DLQI score at 8 weeks after treatment.
Time frame: 8 weeks
Change in Pruritus Severity Using Numerical Rating Scale
Difference between baseline pruritus numerical rating score (0-10 scale) and score at 8 weeks.
Time frame: 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.